ARMATA PHARMACEUTICALS ARMP 深 沪
等待开盘 09-11 09:30:00 美东时间
2.98
+0.031
+1.06%
华盛通- 最 高2.9825
- 今 开2.83
- 成交量 5328股
- 最 低 2.83
- 昨 收 2.9487
- 总市值 1.08亿
- 52周最高 3.14
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.8981
- 委 比 0.00%
- 总股本 3619.35万
- 历史最高 10.48
- 量 比 0.23
- 振 幅 5.17%
- 历史最低 0.8311
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Armata Pharmaceuticals Advances Cystic Fibrosis Infection Treatment With Phage Research
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of
09-08 19:11
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES, Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceutica...
09-08 19:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Armata Pharmaceuticals Files For Mixed Shelf Of Up To $100M
https://www.sec.gov/Archives/edgar/data/921114/000110465925077648/tm2523066d1_s3.htm
08-14 05:20
Armata Pharmaceuticals Q2 EPS $(0.45) Misses $(0.39) Estimate, Sales $2.169M Beat $1.380M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 80 percent decrease over losses of $(0.25) per share
08-13 04:32
美股机会日报丨大摩喊话超配美股！中概股业绩“大丰收”，百度、文远知行盘前齐涨
中概股业绩“大丰收”！百度、文远知行、爱奇艺盘前齐涨；大摩喊话超配美股：标普500指数将升至6500点；“木头姐”连续两日加仓台积电>>
05-21 20:14
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
Armata Pharmaceuticals shares are trading after the comapny announced topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous administered multi-phage therapeutic for the treatment of Staphylococcus aureus bacteremia, in the intent-to-treat population.
Armata Pharmaceuticals shares are trading after the comapny announced topline r...
05-20 00:53
Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.38) by 47.37 percent. This is a 71.01 percent increase over losses of $(0.69) per share
05-15 04:23
